National Institutes of Health (NIH) Human Genome Research Institute: Serious Adverse Drug Reaction Research (R21)

This opportunity uses the R21 Exploratory/Developmental Research Grants funding mechanism.

This Funding Opportunity Announcement is to support research grants that will advance the state of knowledge of serious adverse drug reactions.

Applications across the spectrum of research are encouraged.

Companion Schemes

Funding & Duration

The combined budget for direct costs for the two year project period may not exceed US $275,000 (approx AUD $350,000) .

No more than US $200,000 (approx AUD $255,000)  may be requested in any single year.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Dates

  • 2 January 2018 – Letter of Intent (LOI) via Grants.Gov submission portal (cc Research Services)
  • 18 January 2018 – full applications submitted for internal review.
  • For Full Applications:
    • complete your RFR through ResearchMaster.
    • when prompted to Select Fund Scheme, use Fund Scheme code 901331

See also Submitting an Application to Research Services for Review

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding and tagged . Bookmark the permalink.

Comments are closed.